Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting (GlobeNewswire) - Jun 13, 2022 - P1/2a | N=55 | ReSPECT (NCT01906385) | Sponsor: Plus Therapeutics | "Plus Therapeutics, Inc...announced it will present positive data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the Phase 1/2a ReSPECT™-GBM dose escalation clinical trial in patients with recurrent glioblastoma (GBM) during an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, on June 14 at 10:20 AM PT in Vancouver, British Columbia, Canada....According to the interim data, 186RNL delivered via convection enhanced delivery (CED) provides direct therapy with high radiation absorbed doses for local tumor control with minimal brain and whole-body radiation exposure. 186RNL's tumor-killing effects were observed when greater than 100 Gy doses are delivered to greater than 80% of a tumor without dose-limiting toxicity....To date, there have been no significant adverse events during the dose escalation."
P1/2 data • CNS Tumor • Glioblastoma • Glioma • Oncology
|